{"editorial":{"content_id":"e31c4587-b633-4b6d-bbcf-933c7d4a41cf","slug":"anvisa-glp-wegovy-20261104-8ab7f3","content_type":"news","title":"巴西Anvisa批准首款口服GLP-1减肥药Wegovy","summary":"巴西国家卫生监督局批准Wegovy（司美格鲁肽）口服剂型注册，成为该国首个获批的口服GLP-1减肥药。","body":"巴西国家卫生监督局（Anvisa）于周三（11月4日）批准了Wegovy（司美格鲁肽）口服给药途径的注册。该产品此前在巴西仅以皮下注射溶液形式提供，此次获批使其成为巴西首个获批用于该国的口服GLP-1受体激动剂。\n\n该药适用于成人肥胖症（BMI≥30 kg/m²）及超重（BMI≥27 kg/m²至<30 kg/m²且至少伴有一种体重相关合并症）的治疗，作为低热量饮食和体育活动的辅助手段。司美格鲁肽通过调节食欲和食物摄入发挥作用，促进体重下降并改善与肥胖相关的代谢指标。\n\n新剂型为每日一次口服片剂，治疗采用逐步递增剂量方案：从1.5 mg开始，增至4 mg和9 mg，直至达到推荐的每日维持剂量25 mg。药物须空腹服用，用少量水送服，至少等待30分钟后方可进食、饮水或服用其他药物。\n\nAnvisa表示，新剂型的获批为患者和医疗专业人员提供了更多治疗灵活性，包括在临床适当情况下、按照获批说明书指导在口服与皮下注射剂型之间转换的可能性。\n\n此次注册批准主要依据名为OASIS 4的3期关键临床试验结果，该研究评估了25 mg口服司美格鲁肽在肥胖或超重伴合并症成人中的有效性。研究随访参与者64周，治疗组平均体重减轻超过13%，显著优于安慰剂组，并在多项心血管代谢健康指标上有所改善。\n\n肥胖是一种慢性、进行性、多因素疾病，与2型糖尿病、高血压、血脂异常、心血管疾病和阻塞性睡眠呼吸暂停等多种临床病症风险增加相关。相关决议为第4.249/2026号，已在《联邦官方公报》上公布。","why_it_matters":null,"cbi_observation":null,"direction_tag":"巴西","primary_category":"科技平台","secondary_topics":["政策","行业趋势","br-health"],"content_level":"编辑整理","event_type":"政策法规","audience_tags":[],"event_location":null,"verification_status":"source_verified","published_at":"2026-11-04T11:01:23.883Z","display_date":"2026-11-04","source_published_at":null,"source_url":"https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-aprova-primeiro-medicamento-de-glp-1-oral-para-obesidade","source_name":"Anvisa","source_language":"pt","author_name":"编辑部","risk_level":"low","risk_flags":[],"opportunity_flags":[],"trend_signals":[]},"intelligence":null,"meta":{"canonical_url":"https://chinabrazilinsight.com/news/anvisa-glp-wegovy-20261104-8ab7f3","api_url":"https://chinabrazilinsight.com/api/public/content/anvisa-glp-wegovy-20261104-8ab7f3","markdown_url":"https://chinabrazilinsight.com/api/public/content/anvisa-glp-wegovy-20261104-8ab7f3?view=markdown","json_url":"https://chinabrazilinsight.com/api/public/content/anvisa-glp-wegovy-20261104-8ab7f3?view=json","last_updated":"2026-11-04T11:01:51.296Z","platform":"China Brazil Insight","platform_url":"https://chinabrazilinsight.com"}}